5-(benzyloxy)pentanenitrile | 91477-32-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(benzyloxy)pentanenitrile
• 英文别名: 5-phenylmethoxypentanenitrile
• CAS: 91477-32-6
• 化学式: C₁₂H₁₅NO
• 分子量: 189.257
• InChiKey: GIACUJPVGHEXPE-UHFFFAOYSA-N

物化性质

• 沸点：
  117-120 °C(Press: 0.5 Torr)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(benzyloxy)pentanenitrile 在 盐酸 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 96.0h， 生成 5-(Benzyloxy)-1,1,1-trimethoxypentane
  参考文献：
  名称：

  [2 + 3] Cycloadditions of Enantiomerically Pure Oxazoline N-Oxides: An Alternative to the Asymmetric Aldol Condensation

  摘要：

  A series of camphor-derived oxazoline N-oxides were obtained by condensation of the appropriate orthoesters with (+)-3-(hydroxyamino)borneol (8). These unstable dipoles were used without isolation in various [2 + 3] asymmetric cyclocondensations. The regio- and diastereoselectivities of these reactions were good to excellent. After functional group transformations, adducts were cleaved by a two--step sequence (i.e., oxidation followed by acidic hydrolysis) giving beta-hydroxy ketones and (+)-3-(hydroxyimino)borneol (19). Asymmetric synthesis of (+)-1,7-dioxaspiro[5.5]-undecan-4-ol, a pheromone of Dacus oleae, was achieved as an application of this new method.

  DOI：

  10.1021/jo00111a033
• 作为产物：
  描述：

  4-溴丁醚苄酯 、 氰化钾 在 甲基三辛基氯化铵 作用下， 以 水 为溶剂， 反应 4.0h， 以86%的产率得到5-(benzyloxy)pentanenitrile
  参考文献：
  名称：

  [2 + 3] Cycloadditions of Enantiomerically Pure Oxazoline N-Oxides: An Alternative to the Asymmetric Aldol Condensation

  摘要：

  A series of camphor-derived oxazoline N-oxides were obtained by condensation of the appropriate orthoesters with (+)-3-(hydroxyamino)borneol (8). These unstable dipoles were used without isolation in various [2 + 3] asymmetric cyclocondensations. The regio- and diastereoselectivities of these reactions were good to excellent. After functional group transformations, adducts were cleaved by a two--step sequence (i.e., oxidation followed by acidic hydrolysis) giving beta-hydroxy ketones and (+)-3-(hydroxyimino)borneol (19). Asymmetric synthesis of (+)-1,7-dioxaspiro[5.5]-undecan-4-ol, a pheromone of Dacus oleae, was achieved as an application of this new method.

  DOI：

  10.1021/jo00111a033

文献信息

• Visible-Light Photocatalysis Employing Dye-Sensitized Semiconductor: Selective Aerobic Oxidation of Benzyl Ethers
  作者：Li Ren、Ming-Meng Yang、Chen-Ho Tung、Li-Zhu Wu、Huan Cong

  DOI：10.1021/acscatal.7b03029

  日期：2017.12.1

  The aerobic oxidation is an attractive approach toward environmentally benign synthesis of fine chemicals. In addition, dye-sensitized semiconductors are underdeveloped photocatalysts for selective organic synthesis. With the aid of catalytic eosin Y-sensitized titanium dioxide, we have developed efficient aerobic photooxidation of benzyl ethers to benzoates, featuring low cost, high atom economy,

  有氧氧化是一种在环境上良性合成精细化学品的有吸引力的方法。另外，染料敏化半导体是用于选择性有机合成的未开发的光催化剂。借助于催化曙红Y敏化的二氧化钛，我们开发了苄基醚有效的好氧光氧化为苯甲酸酯的方法，具有低成本，高原子经济性，广泛的底物范围和用户友好的设置的特点。此外，初步的机理研究表明，反应途径可能需要通过可分离的过氧化物中间体进行光诱导的基于自由基的两步过程。
• Thiocyanate radical mediated dehydration of aldoximes with visible light and air
  作者：Yong-Liang Ban、Jian-Ling Dai、Xiao-Ling Jin、Qing-Bao Zhang、Qiang Liu

  DOI：10.1039/c9cc05354a

  日期：——

  We developed a new means of activating aldoximes by an in situ generated thiocyanate radical from ammonium thiocyanate and molecular oxygen at room temperature. With a catalytic amount of organic dye aizenuranine as the photocatalyst, the dehydration of aldoximes proceeds smoothly under visible light irradiation, providing a simple to handle, excellent functional group tolerance, and metal-free protocol

  我们开发了一种通过在室温下从硫氰酸铵和分子氧中原位生成的硫氰酸根来活化醛肟的新方法。用催化量的有机染料壬酸鸟嘌呤作为光催化剂，醛肟的脱水在可见光照射下平稳进行，提供了简单的操作，优异的官能团耐受性和适用于多种腈的无金属方案。
• [EN] NLRP3 MODULATORS<br/>[FR] MODULATEURS DE NLRP3
  申请人：INNATE TUMOR IMMUNITY INC

  公开号：WO2019014402A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

  本发明提供了Formula (I)的化合物：(I)其中所有变量均如本文所定义。这些化合物是NLRP3的调节剂，可用作治疗增殖性疾病的药物，例如在受试者（例如人类）中的癌症治疗。
• Guanidinoheterocyclic derivatives as histamine H-2 antagonists
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0061318A2

  公开（公告）日：1982-09-29

  This invention relates to alcohol derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I:- in which R1 and R2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R1 and R2 is halogen-substituted, or R2 is hydrogen and R1 is RS-E-W- in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyl, E is 0, S, SO, S02 or NR6 in which R6 is H or 1-6C alkyl, R5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R5 and R6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R2 is hydrogen and R1 is hydrogen or 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl, the aryl, arylalkyl and aroyl radicals being optionally substituted; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene or a 1-8C alkylene into which is optionally inserted one or two groups; D is oxygen or sulphur; R3, R4 and R5 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及组胺 H-2 拮抗剂和抑制胃酸分泌的醇衍生物。根据本发明提供了一种式 I 的胍衍生物 其中 R1 和 R2，相同或不同，是氢或 1-10C 烷基、3-8C 环烷基或 4-14C 环烷基烷基，每个烷基、环烷基或环烷基烷基可选带一个或多个 F、Cl 或 Br 原子，条件是 R1 和 R2 中的一个是卤素取代的，或 R2 是氢，R1 是 RS-E-W-，其中 W 是可选被 1 或 2 个 1-4C 烷基取代的 2-6C 亚烷基，E 是 0、S、SO、S02 或 NR6，其中 R6 是 H 或 1-6C 烷基、R5 是 H 或被 1 或 2 个 1-4C 烷基任选取代的 1-6C 烷基，或 R5 和 R6 连接形成吡咯烷、哌啶、吗啉、哌嗪或 N-甲基哌嗪环，或 R2 是氢，R1 是氢或 1-10C 烷基、3-8C环烷基、4-14C环烷基、3-6C烯基、3-6C炔基、1-6C烷酰基、6-10C芳基、7-11C芳烷基或 7-11C芳基，芳基、芳烷基和芳基可任选被取代；环 X 是本说明书中定义的杂环； A 是亚苯基或 5-7C 环亚烷基或 1-8C 亚烷基，其中可选择插入一个或两个基团； D 是氧或硫； R3、R4 和 R5 是氢或本说明书中描述的各种基团：及其药学上可接受的酸加成盐。还描述了制造工艺和药物组合物。
• NLRP3 modulators
  申请人：Innate Tumor Immunity, Inc.

  公开号：US11344543B2

  公开（公告）日：2022-05-31

  The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

  本发明提供了式 (I) 的化合物：(I)，其中所有变量如本文所定义。这些化合物是 NLRP3 的调节剂，可用作治疗受试者（例如人类）增殖性疾病（如癌症）的药物。